Cancers, Vol. 11, Pages 861: Outcomes and Quality of Life of Systemic Therapy in Advanced Hepatocellular Carcinoma

Cancers, Vol. 11, Pages 861: Outcomes and Quality of Life of Systemic Therapy in Advanced Hepatocellular Carcinoma Cancers doi: 10.3390/cancers11060861 Authors: Kehua Zhou Christos Fountzilas Hepatocellular carcinoma (HCC) is one of the most commonly diagnosed cancers worldwide; most patients are diagnosed with advanced disease for which there is no known cure. Tremendous progress has been made over the past decade in the development of new agents for HCC, including small-molecule kinase inhibitors such as sorafenib, lenvatinib, cabozantinib, regorafenib, and monoclonal antibodies like ramucirumab, nivolumab, and pembrolizumab. Ideal use of these agents in clinics has improved the long-term outcome of patients with advanced HCC as well as introduced unique toxicities that can affect quality of life. These toxicities usually are thought to be partially related to cirrhosis, a major risk factor for the development of HCC and a pathophysiological barrier complicating the optimal delivery of antineoplastic therapy. Additionally, side effects of medications together with advanced HCC symptoms not only decrease quality of life, but also cause treatment interruptions and dose reductions that can potentially decrease efficacy. Physicians caring for patients with advanced HCC are called to optimally manage HCC along with cirrhosis in order to prolong life while at the same time preserve the quality of life. In this review, we aimed to summarize outcomes and quality of life w...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research